Modeled dalbavancin transmembrane clearance during intermittent and continuous renal replacement therapies

Blood Purification

Volumn 30, Issue 1, 2010, Pages 37-43

  Vilay, A Mary ^b,e,f   Shah, Krishna H ^a,e   Churchwell, Mariann D ^c,e   Patel, Jignesh H ^d,e   Depestel, Daryl D ^d,e   Mueller, Bruce A ^d,e  

^a University of Bath   (United Kingdom)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c UNIVERSITY OF TOLEDO   (United States)

^d Social and Administrative Sciences   (Australia)

^e UNIVERSITY OF MICHIGAN   (United States)

^f UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Continuous renal replacement therapy; Dalbavancin; Hemodialysis; Solute clearance

Indexed keywords

DALBAVANCIN;

ARTICLE; ARTIFICIAL KIDNEY; DRUG CLEARANCE; HEMODIALYSIS; HEMOFILTRATION; KIDNEY CLEARANCE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; ULTRAFILTRATION;

COMPUTER SIMULATION; HEMOFILTRATION; HUMANS; MEMBRANES, ARTIFICIAL; RENAL DIALYSIS; TEICOPLANIN; UREA;

EID: 77953956993     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000316685     Document Type: Article

References (25)

1. Hoen B, Paul-Dauphin A, Hestin D, Kessler M: EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9: 869-876.
2. Reynvoet E, Vandijck DM, Blot SI, Dhondt AW, De Waele JJ, Claus S, Buyle FM, Vanholder RC, Hoste EA: Epidemiology of infection in critically ill patients with acute renal failure. Crit Care Med 2009; 37: 2203-2209.
3. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. U.S. Renal Data System, USRDS
4. - 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, 2008.
5. de Mendonca A, Vincent JL, Suter PM, Moreno R, Dearden NM, Antonelli M, Takala J, Sprung C, Cantraine F: Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Med 2000; 26: 915-921.
6. Buckwalter M, Dowell JA: Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacol 2005; 45: 1279-1287.
7. Lin SW, Carver PL, DePestel DD: Dalbavancin: a new option for the treatment of gram-positive infections. Ann Pharmacother 2006; 40: 449-460.
8. Leighton A, Gottlieb AB, Dorr MB, Jabes D, Mosconi G, VanSaders C, Mroszczak EJ, Campbell KC, Kelly E: Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 2004; 48: 940-945.
9. Marbury T, Dowell JA, Seltzer E, Buckwalter M: Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment. J Clin Pharmacol 2009; 49: 465-476.
10. Scott MK, Macias WL, Kraus MA, Clark WR, Carfagna MA, Mueller BA: Effects of dialysis membrane on intradialytic vancomycin administration. Pharmacotherapy 1997; 17: 256-262.
11. Pasko DA, Churchwell MD, Mueller BA: Development of an in vitro model of continuous renal replacement therapy (CRRT) solute removal. Blood Purif 2004; 22: 236 (A16).
12. Churchwell MD, Pasko DA, Mueller BA: Daptomycin clearance during modeled continuous renal replacement therapy. Blood Purif 2006; 24: 548-554.
13. Churchwell MD, Pasko DA, Btaiche IF, Jain JC, Mueller BA: Trace element removal during in vitro and in vivo continuous haemodialysis. Nephrol Dial Transplant 2007; 22: 2970-2977.
14. Stevenson JM, Patel JH, Churchwell MD, Vilay AM, Depestel DD, Sorgel F, Kinzig M, Jakob V, Mueller BA: Ertapenem clearance during modeled continuous renal replacement therapy. Int J Artif Organs 2008; 31: 1027-1034.
15. Churchwell MD, Pasko DA, Smoyer WE, Mueller BA: Enhanced clearance of highly protein-bound drugs by albumin-supplemented dialysate during modeled continuous hemodialysis. Nephrol Dial Transplant 2009; 24: 231-238.
16. Fleming GM, Salama NN, Eid SK, Cooke KR, Mueller BA: Etanercept clearance during an in vitro model of continuous venovenous hemofiltration. Blood Purif 2009; 28: 348-353.
17. Patel JH, Churchwell MD, Seroogy JD, Barriere SL, Grio M, Mueller B: Telavancin and hydroxy propyl-beta-cyclodextrin clearance during continuous renal replacement therapy: an in vitro study. Int J Artif Organs 2009; 32: 745-751.
18. Brunet S, Leblanc M, Geadah D, Parent D, Courteau S, Cardinal J: Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis 1999; 34: 486-492.
19. Troyanov S, Cardinal J, Geadah D, Parent D, Courteau S, Caron S, Leblanc M: Solute clearances during continuous venovenous haemofiltration at various ultrafiltration flow rates using Multiflow-100 and HF1000 filters. Nephrol Dial Transplant 2003; 18: 961-966.
20. Fresenius Medical Care North America: Optiflux F200NR, F180NR, F160NR hollow fiber dialyzers, package insert. Waltham, 2007.
21. Fresenius Medical Care North America: Fresenius: Optiflux F200A, F180A, F200B, B180B; Hemoflow F60A, F80A, F60B, F80B, F60M, F80M, F5, F6, F8 hollow fiber dialyzer, package insert. Waltham, 2007.
22. Levy G: Pharmacokinetics in renal disease. Am J Med 1977; 62: 461-465.
23. Macias WL, Mueller BA, Scarim SK: Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance. Clin Pharmacol Ther 1991; 50: 688-694.
24. Mueller BA, Scarim SK, Macias WL: Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. Am J Kidney Dis 1993; 21: 172-179.
25. Finkel KW, Foringer JR: Safety of regional citrate anticoagulation for continuous sustained low efficiency dialysis (C-SLED) in critically ill patients. Ren Fail 2005; 27: 541-545.